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Background: To evaluate the factors affecting the maximum standardized uptake value (SUVmax) of metastatic
lymph nodes in different histological types of non-small cell lung cancer (NSCLC) on integrated positron emission
tomography and computed tomography (PET-CT).
Methods: This was a retrospective, single-institution review of 122 patients with pathologically proven NSCLC who
had PET-CT scanning at the same center. Lymph node metastases were pathologically confirmed in tissue specimens
from surgical patients. Statistical evaluation of PET-CT results was performed on a per-nodal-station basis.
Results: The tumor SUVmax of squamous cell carcinoma (SCC) (11.0 ± 4.1) was higher than that of adenocarcinoma
(AC) (7.4 ± 4.4) (P < 0.01), however, the SUVmax of the metastatic lymph nodes did not differ between the SCC (4.6 ±
3.1) and AC groups(3.6 ± 2.5) (P = 0.221). The SUVmax of metastatic lymph nodes was positively correlated with lymph
node size but not with the primary tumor SUVmax, primary tumor size, tumor location and tumor differentiation.
The frequency of a SUVmax of lymph nodes ≥2.5 was 44%, 80%,100% in SCC group and 39%, 59%, 90% in AC group
when the short-axis diameter of metastatic lymph node was <10 mm, 10–15 mm, and > 15 mm, respectively. The
low sensitivity for metastatic lymph nodes on PET-CT was increased when the SUVmax cut-off for malignancy was
considered to be above the normal background compared with that when the SUVmax cut-off was above 2.5.
Conclusions: There was no difference in the SUVmax of metastatic lymph nodes in the SCC and AC groups. The
SUVmax of metastatic lymph nodes was positively correlated with metastatic lymph node size. There was a high false
negative rate if lymph nodes with a short-axis diameter less than 10 mm and a extremely low false negative rate if
lymph nodes with a short-axis diameter higher than 15 mm. Although an increased sensitivity may be achieved by
decreasing the SUVmax cut-off, invasive staging may still be required for negative lymph nodes due to the lower
sensitivity of PET-CT in both SCC and AC.
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Lung cancer is the most commonly diagnosed cancer
and the leading cause of cancer-related deaths world-
wide [1]. Non-small cell lung cancer (NSCLC), which
mainly includes squamous cell carcinoma (SCC) and
adenocarcinoma (AC), accounts for 80% of lung cancer
cases. Accurate lymph node (LN) staging of NSCLC is
one of the most important factors in the selection of ap-
propriate treatment and in the determination of patient
prognosis. Incorrect staging of NSCLC can result in un-
necessary thoracotomies and early local or distant re-
lapse after surgery [2,3].
Since 2001, integrated positron emission tomography
and computed tomography (PET-CT), which provides
both morphological and metabolic information, has been
increasingly used for assessing lymph node metastases in
patients with NSCLC because of its advantages of safety
and accuracy. The rationale for using FDG-PET in on-
cology is its ability to measure the increased glucose
metabolism of tumor cells. A maximum standardized
uptake value (SUVmax) greater than 2.5 is usually used
as a cut-off value for malignancy [4]. Recent studies have
shown that PET-CT can provide high specificity in LN
staging in NSCLC. However, the sensitivity of PET-CT
in mediastinal LN staging varies from 40–86.3% [5-12];
thus, there is a significant number of false-positive and
false-negative findings in LN staging of lung cancer. The
major reasons for the false-positive and false-negative
findings in LN staging are lymph node involvement
resulting from inflammatory diseases and microscopic
metastases [5-12]. The ability of PET-CT to directly as-
sess each lymph node station is limited; therefore, other
approaches need to be explored to increase the accuracy
of LN staging of NSCLC.
Some relevant studies have shown that primary tu-
mors with different histological types produce different
SUVmax values on integrated PET-CT. SCC exhibited
higher SUVmax values than AC [13-15]. However, it still
remains unclear whether the histological type of NSCLC
affects the assessment of thoracic metastatic lymph
nodes and which other factors may influence the SUV-
max of metastatic lymph nodes on PET-CT. Thus, the
purpose of this study was to evaluate the factors that affect
the detection of metastatic lymph nodes in different
NSCLC types (SCC and AC) by comparing pre-operative




This study retrospectively reviewed 122 consecutive pa-
tients with pathologically proven NSCLC (SCC and AC)
who underwent surgery and had integrated PET-CT
scanning between February 2008 and April 2013 at FirstAffiliated Hospital, College of Medicine, Zhejiang Univer-
sity. This retrospective study was approved by the review
board of First Affiliated Hospital, College of Medicine,
Zhejiang University,which waived the requirement for pa-
tients’ informed consent.
In addition to integrated PET-CT, all patients under-
went a conventional diagnostic workup, including a thor-
ough history, physical examination, laboratory tests and
contrast-enhanced chest CT, to evaluate the condition of
the brain, bones and abdomen.
Patients who received induced chemotherapy and/or ra-
diation therapy, patients who had diabetes mellitus or a
high serum glucose level (greater than 150 mg/dL) at the
time of PET-CT examination and patients with histo-
logical types other than SCC and AC were excluded.
We retrospectively collected data on the enrolled pa-
tients and prospectively compiled an electronic database.
Integrated PET-CT
All PET-CT images were obtained using a combined
PET-CT scanner (Biograph Sensation 16, LSO 39 ring,
Siemens Medical, Erlangen, Germany). All patients were
asked to fast for at least 6 h before the examination and
then received an intravenous injection of FDG at 5.5-
7.4 MBq (0.15-0.20 mCi)/kg of body weight. After 1 h,
the patients were scanned from the head to mid-thigh
using an integrated PET-CT system. First, a 16-section
multi-detector row CT scan was performed at 120 kV
and 50 mA. Then, with a tube rotation time of 0.5 sec-
onds, a 2.5-mm-thick section was matched to the PET
section thickness, followed by a three-dimensional PET
with the patient in the same supine position. The PET
emission scan covered the region from the subcranium
to the mid-thigh. The brain scan required another bed
position, and the acquisition time was 2 minutes per bed
position. Attenuation correction was based on CT. The
PET images were iteratively reconstructed using ordered
subset Syngo Speaking software (Wizard Workstation;
Siemens Medical). PET, CT and fused PET/CT images
were generated and reviewed on a computer, and co-
registered images were displayed on a workstation.
Two experienced nuclear medicine physicians who were
aware of the clinical and stand-alone contrast-enhanced
CT results, but were blinded to the histological findings,
evaluated the PET-CT data side by side in consensus. A
lesion with increased FDG uptake in three planes com-
pared with background or with a SUVmax above 2.5 on
PET scan was classified as malignant. Then, the SUVmax
and diameter of the primary tumors and short-axis diam-
eter of lymph nodes were measured and collected.
Surgery and histopathology
A total of 122 patients underwent surgical resections
and nodal dissections at First Affiliated Hospital, College
Table 1 Characteristics of primary tumors and lymph
nodes in NSCLC
Parameter SCC(n = 41) AC(n = 81) P
Tumour diameter
(mm ± SD)
39.5 ± 10.2 25.5 ± 8.9 <0.001
Tumour SUVmax(±SD) 11.0 ± 4.1 7.4 ± 4.4 <0.001
Metastastic lymph nodes
diameter (mm ± SD)
11.9 ± 3.7 12.7 ± 4.5 0.635
Metastastic lymph nodes
SUVmax (±SD)








Table 2 The associations of tumor size, tumor SUVmax,
tumor differentiation, tumor location, lymph node size
and tumor pathological type with metastatic lymph node
SUVmax were analyzed, using linear regression model of
general evaluation equation (GEE)
Variable Class β se P
Tumor size 0.03 0.09 0.7069
Tumor SUVmax 0.03 0.03 0.3429
Tumor differentiation High Ref – –
Median −0.04 0.62 0.9526
Low −0.48 0.58 0.4035
Tumor location Central Ref – –
Peripheral 0.05 0.35 0.8917
Lymph node size 0.17 0.04 <0.0001
Pathological type Squamous cancer Ref – –
Adenocarcinoma −0.16 0.4 0.6872
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included pneumonectomy (n = 2), bilobectomy (n = 14),
lobectomy (n = 88) and segmentectomy (n = 18). All
resected tumor specimens were examined and classified
based on the World Health Organization (WHO) classi-
fication. The dissected lymph nodes were stained by
hematoxylin and eosin and then histologically examined.
These pathological examinations were all performed by
experienced pulmonary pathologists at the same hos-
pital. By retrospectively reviewing the pathological re-
sults of the enrolled patients, we collected information
on the diameter and SUVmax of the primary tumors,
short-axis diameter of thoracic lymph nodes, patho-
logical type, tumor location and tumor differentiation.
Data analysis
Continuous data are reported as medians, variances and
ranges, while categorical data are reported as counts and
percentages. The sensitivity, specificity and accuracy of
integrated PET-CT in assessing lymph node metastases
were determined based on the histological results as the
reference standard. Correlation between the SUVmax of
metastatic lymph nodes and potential covariates was
performed using a linear regression model of general
evaluation equation, and the chi-square test was used
for categorical data (sensitivity, specificity and accuracy).
All P values were two-sided, and a P value <0.05 was
considered statistically significant. All analyses were con-
ducted using the SPSS 16.0 software package.
Results
Subjects
The study population included 122 patients who under-
went surgery; SCC and AC were the final diagnoses in
41 (33.6%) and 81 (66.4%) patients, respectively. The
median ages of the SCC and AC patients were 61.9 ±
11.2 and 61.5 ± 10.7 years, respectively. A total of 511
nodal stations were evaluated, including 195 in the SCC
group and 316 in the AC group. A total of 27 of 195
SCC nodal stations and 80 of 316 AC nodal stations
were pathologically positive for malignancy.
Characteristics of tumors and lymph nodes according to
histological type
The characteristics of primary tumors and lymph nodes
are summarized in Table 1 according to histological
type. Among all enrolled patients, the mean SCC and
AC diameters were 39.5 ± 10.2 and 25.5 ± 8.9 mm, re-
spectively (P < 0.01), and the mean SUVmax of SCCs
and ACs was 11.0 ± 4.1 and 7.4 ± 4.4, respectively (P <
0.01). The SUVmax of the metastatic lymph nodes in
the SCC and AC groups was 4.6 ± 3.1 and 3.6 ± 2.5, re-
spectively (P = 0.221). The diameter of the metastaticlymph nodes was 11.9 ± 3.7 mm and 12.7 ± 4.5 mm in
the SCC and AC groups, respectively (P = 0.877).
Correlation between the SUVmax of metastatic lymph
nodes and potential covariates
The factors that may affect the SUVmax of metastatic
lymph nodes in NSCLC patients have not been deter-
mined. We analyzed the correlation between the SUV-
max of metastatic lymph nodes and other factors such
as the primary tumor SUVmax and size, metastatic
lymph node size, primary tumor location, tumor differ-
entiation and histological type using linear regression
model of general evaluation equation (Table 2). Only
lymph node size was significantly related to the SUVmax
of metastatic lymph nodes (P <0.0001). The SUVmax
and size of the primary tumor, the location of the
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type had no correlation with the SUVmax of metastatic
lymph nodes. Table 3 shows the relationship between
the metastatic lymph node size and the frequency of a
SUVmax of lymph nodes ≥ 2.5. Our study demonstrates
that the frequency of a SUVmax of lymph nodes ≥2.5
was 44%, 80%,100% in SCC group and 39%, 59%, 90% in
AC group when the metastatic lymph size was <10 mm,
10–15 mm, and >15 mm, respectively.
Sensitivity, specificity and accuracy of PET-CT based on
different SUVmax cut-offs
For criterion 1, the lymph nodes were deemed malignant
when their SUVmax was higher than the normal back-
ground. According to criterion 1, in the SCC group, 14
nodal stations were false-negatives, and 13 nodal stations
were true-positives; in the AC group, 46 nodal stations
were false-negatives, and 34 nodal stations were true-
positives. The sensitivity, specificity and accuracy were
48.1%, 88.1% and 82.6%, respectively, in the SCC group
(Table 4) and 57.5%, 95.9% and 86.3%, respectively, in
the AC group (Table 5) based on a per-nodal analysis.
For criterion 2, the lymph nodes were deemed malig-
nant when their SUVmax was above 2.5. The sensitivity,
specificity and accuracy were 37.0%, 90.5% and 83.1%,
respectively, in the SCC group (Table 4) and 40.0%,
96.3% and 82.3%, respectively, in the AC group (Table 5)
according to criterion 2. The difference in the specificity
and accuracy in both the SCC and AC groups was not
significant between criterion 1 and criterion 2. However,
the sensitivity was higher when criterion 1 was used
compared with criterion 2 (P < 0.01).
Discussion
In keeping with published reports, the SUVmax of the
primary tumor was significantly higher in the SCC group
(11.0 ± 4.1) than in the AC group (7.4 ± 4.4) [16,17]. Al-
though the uptake mechanism and biochemical path-
ways of FDG are not completely understood, previous
studies showed that glucose transporters (Gluts) are
important factors that influence FDG uptake by malig-
nant tumors and that Glut-1 is the principal subtype in
NSCLC. It was reported that the degree of Glut-1 ex-
pression in SCC is higher than that in AC, which may
partly explain why the SUVmax of SCC is higher thanTable 3 Relationship between lymph node size and
frequency of SUVmax ≥ 2.5
Range of lymph
node size
Frequency of SUVmax ≥ 2.5
SCC AC
<10 mm 44% 39%
10 mm≤, ≤15 mm 80% 59%
15 mm< 100% 90%that of AC [18-20]. It also has been reported that the
SUVmax of NSCLC is positively correlated with tumor
size. In our study, we found that the primary tumor size
of SCC was significantly greater than that of AC, which
could be another cause of the higher tumor SUVmax in
the SCC group.
Although it is indicated that the SUVmax of SCC is
higher than that of AC, it still remains unclear whether
the SUVmax of metastatic lymph nodes in SCC patients
is also higher than that in AC patients. Our study
showed that there was no difference in the SUVmax of
metastatic lymph nodes between the SCC (4.6 ± 3.1) and
AC groups (3.6 ± 2.5). This result demonstrated that the
histological type of NSCLC does not affect the SUVmax
of metastatic lymph nodes even though it influences the
SUVmax of the primary tumor. In this study, multivari-
able linear regression revealed that the SUVmax of
metastatic lymph nodes had a positive correlation with
lymph node size, but the SUVmax and size of the pri-
mary tumor, location of the primary tumor, and tumor
differentiation had no influence on the SUVmax of
metastatic lymph nodes. This result indicates that the
size of the lymph nodes may be the key factor that af-
fects the SUVmax of metastatic lymph nodes. Our study
also showed that when the short-axis diameter of the
lymph node was <10 mm, only 44% of metastatic lymph
nodes in SCC group, 39% of metastatic lymph nodes in
AC group had a SUVmax higher than 2.5, whereas about
100% of metastatic lymph node in SCC group and 90%
of metastatic lymph node in AC group had a SUVmax
higher than 2.5 when the short-axis diameter of the
lymph node was >15 mm. Bille et al. [21] analyzed the
factors associated with metastatic lymph node detection
in patients with AC vs. SCC, and they found that in the
AC group, the mean diameter of false-negative lymph
nodes was 7 ± 2.5 mm, compared with the 12.5 ± 4 mm
diameter of true-positive lymph nodes. In the SCC
group, the mean diameter of false-negative lymph nodes
was 7.4 ± 2.8 mm, compared with the 14.7 ± 6 mm diam-
eter of true-positive lymph nodes. Regarding nodal size,
the PET-CT sensitivity in detecting malignant involve-
ment was 32.4% in nodes <10 mm and 85.3% in nodes
≥10 mm [11]. According to the above results, we may
have to do with the fact that there is a higher false-
negative rate if the diameter of the lymph node is
<10 mm, and a extremely low false-negative rate if the
diameter of the lymph node is >15 mm in both SCC and
AC. Nambu et al. [22] found that lymph node metasta-
ses were more commonly observed in NSCLC cases with
a higher tumor SUVmax. The frequency of lymph node
metastases was 70% in NSCLC patients with a tumor
SUVmax greater than 12, whereas no lymph node me-
tastases were found in NSCLC patients with a tumor
SUVmax less than 2.5. These results suggest that lung
Table 4 Contingency table for PET-CT in identifying lymph node metastases in SCC group










PET-CT(+) 13 12 25 10* 16 26
PET-CT(−) 14 156 170 17 152 169
Total 27 168 195 27 168 195
Criterion 1: Sensitivity: 48.1%; Specificity: 88.1%; Accuracy: 82.6%.
Criterion 2: Sensitivity: 37.0%*; Specificity: 90.5%; Accuracy: 83.1%.
*Means the difference in the sensitivity was significant (P < 0.01) between criterion 1 and criterion 2 in SCC group.
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have a high risk for lymph node metastases. Similar re-
sults have also been reported in other studies [4,23].
However, our study revealed that there is no correlation
between the SUVmax of the primary tumor and the
SUVmax of the metastatic lymph node, which may due
to the smaller sample size in our study. In clinical prac-
tice, it is challenging to distinguish metastatic lymph
nodes from benign lymph nodes, especially for those
lymph nodes with a short-axis diameter of less than
10 mm, which are always classified as negative for metas-
tasis before surgery. According to the studies mentioned
above, we believe that those lymph nodes with a short-
axis diameter less than 10 mm should not be classified as
negative despite having a SUVmax score of less than 2.5.
If those small size lymph nodes have a higher primary
tumor SUVmax, there is a high probability of metastasis,
and further invasive procedures such as EBUS-TBNA,
mediastinoscopy or VATS may be considered.
Previous studies indicated that PET-CT has a low sen-
sitivity and a relatively high specificity for detecting thor-
acic lymph node metastases. However, to date, the ideal
SUVmax cut-off for distinguishing malignant from be-
nign thoracic lymph nodes has not been determined.
Most studies have defined a SUVmax of 2.5 as the upper
limit of normal lymph nodes. However, this cut-off is
purely arbitrary. Some previous studies also considered
positive mediastinal lymph nodes to be nodes that ex-
hibit focally increased 18-FDG uptake above the normal
background activity. In our study, we found that using
the SUVmax cut-off of 2.5 resulted in a considerable







PET-CT(+) 46 10 56
PET-CT(−) 34 232 26
Total 80 242 32
Criterion 1: Sensitivity: 57.5%; Specificity: 95.9%; Accuracy: 86.3%.
Criterion 2: Sensitivity: 40.0%*; Specificity: 96.3%; Accuracy: 82.3%.
*Means the difference in the sensitivity was significant (P < 0.01) between criterionlymph nodes. In order to determine whether the sensi-
tivity could be improved by adjusting the criteria, we
compared the sensitivity, specificity and accuracy of
PET-CT in detecting metastatic lymph nodes using two
different SUVmax cut-offs.
Our study showed that there was no significant differ-
ence in the specificity and accuracy of the two criteria in
either the SCC or AC group. The sensitivity in the AC
and SCC groups detected using criterion 1 was signifi-
cantly higher than that using criterion 2. The different
SUVmax cut-offs significantly affected the sensitivity but
not the specificity. Therefore, we suppose that a SUV-
max cut-off value of 2.5 for detecting metastatic lymph
nodes may not be optimal for sensitivity because lymph
nodes with a slight SUVmax increase may be associated
with a missed diagnosis. Bille et al. assessed the sensitiv-
ity, specificity and accuracy of PET-CT for detecting
lymph node metastasis in different histological types of
NSCLC; lymph nodes were deemed positive for meta-
static spread if they exhibited focally increased FDG up-
take that was higher than the normal background
activity [22]. The study showed that the sensitivity, spe-
cificity and accuracy of PET-CT were 53.8, 91.5 and
79.1%, respectively, in the AC group and 87.5, 81.8 and
83.5%, respectively, in the SCC group. Although the sen-
sitivity may be increased when lymph nodes are defined
as malignant when their SUVmax is higher than the
background, this scenario will also increase the possibil-
ity of a false positive result. Therefore, the results of this
preliminary study need to be confirmed.
Our study has several limitations. First, this study was








6 48 233 281
2 80 242 322
1 and criterion 2 in AC group.
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and the study population consisted of only patients who
underwent surgery; thus, a definitive conclusion cannot be
drawn.
Conclusions
In conclusion, there is no difference in SUVmax of thor-
acic metastatic lymph nodes between SCC group and
AC group, and the SUVmax of thoracic metastatic
lymph nodes is mainly related to their size in both SCC
and AC patients. There was a high false negative rate if
lymph nodes with a short-axis diameter less than 10 mm
and a low false negative rate if lymph nodes with a
short-axis diameter higher than 15 mm. There was a low
sensitivity and high specificity and accuracy of PET-CT
in assessing malignant thoracic lymph nodes in both
SCC and AC patients; the sensitivity may increased when
the SUVmax cut-off for distinguishing malignant thoracic
lymph nodes was considered to be above the normal back-
ground. The results of this study need to be confirmed by
prospective studies with larger sample sizes.
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